BIOMAT Database Logo BIOMAT Database Logo

Clearance of serum hepatitis C virus RNA after interferon therapy in relation to virus genotype. 1995

K Kanai, and M Kako, and T Aikawa, and T Kumada, and T Kawasaki, and T Hatahara, and Y Oka, and M Mizokami, and T Sakai, and K Iwata
Department of Gastroenterology, Toshiba General Hospital, Tokyo, Japan.

The effect of recombinant interferon-alfa on serum HCV RNA levels in Japanese patients with chronic hepatitis C was investigated. At 24 weeks of treatment, 41 (32.5%) of 126 patients lost HCV RNA from serum, and aminotransferases were normalized in 31 (75.6%) of these 41 cases. HCV genotypes were categorized into four types (Type I, II, III, IV); the frequencies among the patients were: Type I: 0%, Type II: 70.6%, Type III: 20.6%, and Type IV: 6.3%. At the end of the 24-week treatment, HCV RNA levels were remarkably decreased in Type III patients and became undetectable in 18 (69.2%) of 26. In contrast, only 18 (20.2%) of 89 patients with Type II and two of eight with Type IV lost HCV RNA from sera. The relation between HCV genotype (Type III) and response to IFN therapy was also confirmed using a logistic regression model. HCV genotype seems to be an important factor in determining the response to IFN in patients with chronic hepatitis C.

UI MeSH Term Description Entries
D007564 Japan A country in eastern Asia, island chain between the North Pacific Ocean and the Sea of Japan, east of the Korean Peninsula. The capital is Tokyo. Bonin Islands
D008297 Male Males
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D005260 Female Females
D005838 Genotype The genetic constitution of the individual, comprising the ALLELES present at each GENETIC LOCUS. Genogroup,Genogroups,Genotypes
D006526 Hepatitis C INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown. Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted,Parenterally-Transmitted Non-A, Non-B Hepatitis,PT-NANBH,Parenterally Transmitted Non A, Non B Hepatitis
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077190 Interferon alpha-2 Alpha interferon encoded by the human IFNA2 gene. Recombinant forms are used in the treatment of CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; KAPOSI SARCOMA; MELANOMA; and HAIRY CELL LEUKEMIA. IFN-alpha 2,IFN-alpha-2,IFNalpha-2b, Recombinant,Interferon alfa-2a,Interferon alfa-2b,Interferon alpha-2b, Recombinant,Interferon alpha-A,Interferon-alpha 2,Intron A (Interferon),LeIF A,Reaferon,Recombinant Interferon alpha-2a,Recombinant Interferon alpha-2b,Ro 22-8181,Roferon-A,Sch-30500,Viferon,IFNalpha 2b, Recombinant,Interferon alfa 2a,Interferon alfa 2b,Interferon alpha 2,Interferon alpha 2b, Recombinant,Interferon alpha A,Interferon alpha-2a, Recombinant,Recombinant IFNalpha-2b,Recombinant Interferon alpha 2a,Recombinant Interferon alpha 2b,Ro 22 8181,Ro 228181,Roferon A,RoferonA,Sch 30500,Sch30500

Related Publications

K Kanai, and M Kako, and T Aikawa, and T Kumada, and T Kawasaki, and T Hatahara, and Y Oka, and M Mizokami, and T Sakai, and K Iwata
Hepatitis C virus genotype, hepatitis C virus RNA titers, and response to interferon.
July 1997, Annals of internal medicine,
K Kanai, and M Kako, and T Aikawa, and T Kumada, and T Kawasaki, and T Hatahara, and Y Oka, and M Mizokami, and T Sakai, and K Iwata
Relation between serum hepatitis C virus-RNA levels and efficacy of interferon-beta therapy.
August 1995, Acta paediatrica Japonica : Overseas edition,
K Kanai, and M Kako, and T Aikawa, and T Kumada, and T Kawasaki, and T Hatahara, and Y Oka, and M Mizokami, and T Sakai, and K Iwata
Predicting interferon therapy efficacy from hepatitis C virus genotype and RNA titer.
May 1994, Digestive diseases and sciences,
K Kanai, and M Kako, and T Aikawa, and T Kumada, and T Kawasaki, and T Hatahara, and Y Oka, and M Mizokami, and T Sakai, and K Iwata
Eradication of hepatitis C virus RNA after alpha-interferon therapy.
August 1994, Annals of internal medicine,
K Kanai, and M Kako, and T Aikawa, and T Kumada, and T Kawasaki, and T Hatahara, and Y Oka, and M Mizokami, and T Sakai, and K Iwata
Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C.
October 1995, Hepatology (Baltimore, Md.),
K Kanai, and M Kako, and T Aikawa, and T Kumada, and T Kawasaki, and T Hatahara, and Y Oka, and M Mizokami, and T Sakai, and K Iwata
Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy.
March 1993, Gastroenterology,
K Kanai, and M Kako, and T Aikawa, and T Kumada, and T Kawasaki, and T Hatahara, and Y Oka, and M Mizokami, and T Sakai, and K Iwata
[Relation between HCV genotype and serum HCV RNA level as predictors of response to interferon-alfa 2b therapy in chronic hepatitis C].
July 1994, Nihon rinsho. Japanese journal of clinical medicine,
K Kanai, and M Kako, and T Aikawa, and T Kumada, and T Kawasaki, and T Hatahara, and Y Oka, and M Mizokami, and T Sakai, and K Iwata
Development of hepatocellular carcinoma after clearance of hepatitis C virus with interferon therapy.
August 1997, The Western journal of medicine,
K Kanai, and M Kako, and T Aikawa, and T Kumada, and T Kawasaki, and T Hatahara, and Y Oka, and M Mizokami, and T Sakai, and K Iwata
Hepatitis C reinfection after liver transplantation in relation to virus genotype.
January 1999, Transplantation proceedings,
K Kanai, and M Kako, and T Aikawa, and T Kumada, and T Kawasaki, and T Hatahara, and Y Oka, and M Mizokami, and T Sakai, and K Iwata
Changes in serum hepatitis C virus RNA titer and response to interferon therapy in patients with chronic hepatitis C.
October 1994, Digestive diseases and sciences,
Copied contents to your clipboard!